Ultragenyx Pharmaceutical
RARE
#3685
Rank
โ‚น313.66 B
Marketcap
โ‚น3,251
Share price
-0.83%
Change (1 day)
-21.97%
Change (1 year)

Revenue for Ultragenyx Pharmaceutical (RARE)

Revenue in 2025 (TTM): โ‚น54.52 Billion

According to Ultragenyx Pharmaceutical's latest financial reports the company's current revenue (TTM ) is โ‚น56.94 Billion. In 2024 the company made a revenue of โ‚น48.06 Billion an increase over the revenue in the year 2023 that were of โ‚น36.15 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Ultragenyx Pharmaceutical from 2013 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) โ‚น54.52 B13.46%
2024 โ‚น48.06 B32.94%
2023 โ‚น36.15 B20.24%
2022 โ‚น30.06 B14.95%
2021 โ‚น26.15 B31.96%
2020 โ‚น19.82 B168%
2019 โ‚น7.39 B105.41%
2018 โ‚น3.60 B2058.95%
2017 โ‚น0.16 B1745.3%
2016 โ‚น9.03 M
2015 N/A
2014 N/A
2013 N/A

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
BioMarin Pharmaceutical
BMRN
โ‚น279.41 B 390.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Amicus Therapeutics
FOLD
โ‚น54.06 B-5.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Esperion Therapeutics
ESPR
โ‚น27.43 B-51.82%๐Ÿ‡บ๐Ÿ‡ธ USA
Lexicon Pharmaceuticals
LXRX
โ‚น6.39 B-88.76%๐Ÿ‡บ๐Ÿ‡ธ USA